risks of microdosing glp 1 Dr. Blum and our patient @wesleyk2 are featured in a Men's Health exclusive for Apple News all about GLP-1s. Check out the full story at the link in our bio! Interested What is GLP-1 Microdosing? |

Clinical trials have shown that discontinuing treatment typically results in gradual weight regain and worsening glycemic control, underscoring that these are chronic disease management tools rather than short-term interventions

At the same time, it was also reported that major Part D plan sponsors were reluctant or unwilling to participate in the BALANCE Model as it was originally designed

[53] The mechanism of action for Rimonabant was cannabinoid receptor CB1 antagonism, in other words, blocking the cannabinoid receptor (the one that weed, for example, binds to and activates in order to make you all happy)

Most adverse effects associated with GLP-1 agonists are mild to moderate and often improve with time